Chenguang Biotech Group Financial Flexibility Index
Chenguang Biotech Group financial flexibility index. Chenguang Biotech Group (300138) has a Financial Flexibility Index of 0.12x as of September 2025. Free cash flow of CN¥562.60 Million (operating CF CN¥524.96 Million minus capex CN¥37.63 Million) represents 0% of total liabilities (CN¥4.57 Billion). See 300138 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Chenguang Biotech Group (2007–2025)
Financial flexibility index of Chenguang Biotech Group from 2007 to 2025. Historical Financial Flexibility Index trend for Chenguang Biotech Group across 19 annual periods. Check Chenguang Biotech Group earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Chenguang Biotech Group Financial Flexibility Index by Year (2007–2025)
Chenguang Biotech Group financial flexibility index by year from 2007 to 2025. Year-by-year free cash flow to debt coverage for Chenguang Biotech Group. For the full cash flow conversion analysis, see 300138 cash generation efficiency.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.06x | CN¥348.16 Million | CN¥212.91 Million | CN¥6.07 Billion | ▲ +559.6% |
| 2024 | -0.01x | CN¥-73.28 Million | CN¥-222.81 Million | CN¥5.87 Billion | ▲ +80.6% |
| 2023 | -0.06x | CN¥-321.71 Million | CN¥-510.91 Million | CN¥5.01 Billion | ▼ -126.2% |
| 2022 | 0.25x | CN¥910.84 Million | CN¥734.81 Million | CN¥3.71 Billion | ▲ +125.9% |
| 2021 | 0.11x | CN¥344.72 Million | CN¥63.90 Million | CN¥3.17 Billion | ▼ -70.8% |
| 2020 | 0.37x | CN¥966.29 Million | CN¥529.41 Million | CN¥2.59 Billion | ▲ +326.7% |
| 2019 | 0.09x | CN¥241.38 Million | CN¥-24.35 Million | CN¥2.77 Billion | ▲ +69.3% |
| 2018 | 0.05x | CN¥83.35 Million | CN¥-56.18 Million | CN¥1.62 Billion | ▲ +454.2% |
| 2017 | -0.01x | CN¥-18.18 Million | CN¥-145.95 Million | CN¥1.25 Billion | ▲ +93.8% |
| 2016 | -0.23x | CN¥-226.80 Million | CN¥-321.62 Million | CN¥967.46 Million | ▼ -1496.6% |
| 2015 | 0.02x | CN¥9.47 Million | CN¥-64.66 Million | CN¥564.12 Million | ▼ -97.3% |
| 2014 | 0.62x | CN¥309.58 Million | CN¥272.96 Million | CN¥499.69 Million | ▲ +889.6% |
| 2013 | 0.06x | CN¥40.15 Million | CN¥-36.47 Million | CN¥641.26 Million | ▲ +470.7% |
| 2012 | -0.02x | CN¥-7.56 Million | CN¥-142.11 Million | CN¥447.73 Million | ▼ -100.9% |
| 2011 | 1.79x | CN¥263.90 Million | CN¥82.18 Million | CN¥147.16 Million | ▲ +516.1% |
| 2010 | -0.43x | CN¥-93.05 Million | CN¥-190.51 Million | CN¥215.92 Million | ▼ -188.0% |
| 2009 | 0.49x | CN¥94.13 Million | CN¥27.23 Million | CN¥192.17 Million | ▲ +231.1% |
| 2008 | 0.15x | CN¥35.11 Million | CN¥9.06 Million | CN¥237.31 Million | ▲ +228.9% |
| 2007 | -0.11x | CN¥-9.81 Million | CN¥-23.02 Million | CN¥85.49 Million | — |